Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer
Immunotherapy has become a very effective treatment for many cancers. It has a unique set of immune system-related adverse effects, collectively known as immune-related adverse events (irAEs). Skin toxicities are the most common irAEs, of which bullous pemphigoid, although rare, is potentially life-...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1124730/full |
| _version_ | 1797871424755466240 |
|---|---|
| author | Ting Wang Qianwen Shao Chunmei Xiao Lianke Liu |
| author_facet | Ting Wang Qianwen Shao Chunmei Xiao Lianke Liu |
| author_sort | Ting Wang |
| collection | DOAJ |
| description | Immunotherapy has become a very effective treatment for many cancers. It has a unique set of immune system-related adverse effects, collectively known as immune-related adverse events (irAEs). Skin toxicities are the most common irAEs, of which bullous pemphigoid, although rare, is potentially life-threatening and affects patients’ survival. In this article, we report the treatment of bullous pemphigoid caused by programmed cell death protein-1 (PD-1) in a case of proficient mismatch repair (pMMR)/microsatellite stable (MSS) colorectal cancer. No significant adverse effects were observed in the patient after methylprednisone was tapered to 4 mg twice a day. No new skin lesions occurred recently in the patient and the original skin lesions healed. In particular, the patient’s immunotherapy was not stopped and the best outcome was a partial remission of the disease, lasting for more than 8 months. |
| first_indexed | 2024-04-10T00:42:41Z |
| format | Article |
| id | doaj.art-3dd713e254ea4e32a8d946fac258de1c |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-10T00:42:41Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-3dd713e254ea4e32a8d946fac258de1c2023-03-14T05:00:47ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-03-011310.3389/fonc.2023.11247301124730Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancerTing WangQianwen ShaoChunmei XiaoLianke LiuImmunotherapy has become a very effective treatment for many cancers. It has a unique set of immune system-related adverse effects, collectively known as immune-related adverse events (irAEs). Skin toxicities are the most common irAEs, of which bullous pemphigoid, although rare, is potentially life-threatening and affects patients’ survival. In this article, we report the treatment of bullous pemphigoid caused by programmed cell death protein-1 (PD-1) in a case of proficient mismatch repair (pMMR)/microsatellite stable (MSS) colorectal cancer. No significant adverse effects were observed in the patient after methylprednisone was tapered to 4 mg twice a day. No new skin lesions occurred recently in the patient and the original skin lesions healed. In particular, the patient’s immunotherapy was not stopped and the best outcome was a partial remission of the disease, lasting for more than 8 months.https://www.frontiersin.org/articles/10.3389/fonc.2023.1124730/fullbullous pemphigoidPD-1fruquintinibsintilimabpMMR/MSS mCRC |
| spellingShingle | Ting Wang Qianwen Shao Chunmei Xiao Lianke Liu Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer Frontiers in Oncology bullous pemphigoid PD-1 fruquintinib sintilimab pMMR/MSS mCRC |
| title | Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer |
| title_full | Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer |
| title_fullStr | Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer |
| title_full_unstemmed | Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer |
| title_short | Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer |
| title_sort | case report bullous pemphigoid associated with sintilimab therapy for pmmr mss colorectal cancer |
| topic | bullous pemphigoid PD-1 fruquintinib sintilimab pMMR/MSS mCRC |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1124730/full |
| work_keys_str_mv | AT tingwang casereportbullouspemphigoidassociatedwithsintilimabtherapyforpmmrmsscolorectalcancer AT qianwenshao casereportbullouspemphigoidassociatedwithsintilimabtherapyforpmmrmsscolorectalcancer AT chunmeixiao casereportbullouspemphigoidassociatedwithsintilimabtherapyforpmmrmsscolorectalcancer AT liankeliu casereportbullouspemphigoidassociatedwithsintilimabtherapyforpmmrmsscolorectalcancer |